{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:17Z","timestamp":1790368097431,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00296-019-04481-8","type":"journal-article","created":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T09:02:16Z","timestamp":1575709336000},"page":"207-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9727-044X","authenticated-orcid":false,"given":"G. S. R. S. N. K.","family":"Naidu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-6652","authenticated-orcid":false,"given":"Shefali Khanna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8091-1952","authenticated-orcid":false,"given":"M. B.","family":"Adarsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-0694","authenticated-orcid":false,"given":"Varun","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3488","authenticated-orcid":false,"given":"Anindita","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-9163","authenticated-orcid":false,"given":"Sahajal","family":"Dhooria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-7655","authenticated-orcid":false,"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,7]]},"reference":[{"key":"4481_CR1","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76:1897\u20131905. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211448","journal-title":"Ann Rheum Dis"},{"key":"4481_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndal","year":"2010","unstructured":"Tyndal AJ, Banert B, Vonk M, Air\u00f2 P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815. https:\/\/doi.org\/10.1136\/ard.2009.114264","journal-title":"Ann Rheum Dis"},{"key":"4481_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","volume":"44","author":"M Rubio-Rivas","year":"2014","unstructured":"Rubio-Rivas M, Royo C, Simeon CP, Corbella X, Fonollosa V (2014) Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44:208\u2013219. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"4481_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/art.22532","volume":"57","author":"Terry A. Mcnearney","year":"2007","unstructured":"McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, Mayes MD (2007) Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 57:318\u2013326. https:\/\/doi.org\/ 10.1002\/art.22532","journal-title":"Arthritis & Rheumatism"},{"key":"4481_CR5","doi-asserted-by":"publisher","first-page":"e0191938","DOI":"10.1371\/journal.pone.0191938","volume":"13","author":"S Dhooria","year":"2018","unstructured":"Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, Aggarwal AN, Behera D (2018) Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. PLoS ONE 13:e0191938. https:\/\/doi.org\/10.1371\/journal.pone.0191938","journal-title":"PLoS ONE"},{"key":"4481_CR6","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa.055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa.055120","journal-title":"N Engl J Med"},{"key":"4481_CR7","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962\u20133970. https:\/\/doi.org\/10.1002\/art.22204","journal-title":"Arthritis Rheum"},{"key":"4481_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double blind, parallel group trial. Lancet Respir Med 4:708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"4481_CR9","doi-asserted-by":"publisher","first-page":"e0124205","DOI":"10.1371\/journal.pone.0124205","volume":"10","author":"MA Omair","year":"2015","unstructured":"Omair MA, Alahmadi A, Johnson SR (2015) Safety and effectiveness of Mycophenolate in systemic sclerosis. A systematic review. PLoS One 10:e0124205. https:\/\/doi.org\/10.1371\/journal.pone.0124205","journal-title":"A systematic review. PLoS One"},{"issue":"Suppl 1","key":"4481_CR10","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1177\/096120330501400102","volume":"14","author":"AC Allison","year":"2005","unstructured":"Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl 1):s2\u20138","journal-title":"Lupus"},{"key":"4481_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.autrev.2015.02.002","volume":"14","author":"M Iudici","year":"2015","unstructured":"Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G (2015) Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmu Rev 14:575\u2013578. https:\/\/doi.org\/10.1016\/j.autrev.2015.02.002","journal-title":"Autoimmu Rev"},{"key":"4481_CR12","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","volume":"15","author":"SA Guler","year":"2018","unstructured":"Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N, Li KH, Dunne J, Wilcox PG, Ryerson CJ (2018) Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann Am Thorac Soc 15:1427\u20131433. https:\/\/doi.org\/10.1513\/AnnalsATS.201806-362OC","journal-title":"Ann Am Thorac Soc"},{"key":"4481_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","volume":"72","author":"M Kolb","year":"2017","unstructured":"Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM (2017) Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 72:340\u2013346. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-208710","journal-title":"Thorax"},{"key":"4481_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"4481_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS\/ERS Task Force (2005) Standardisation of spirometry. Eur Respir J 26:319\u2013338. https:\/\/doi.org\/10.1183\/09031936.05.00034805","journal-title":"Eur Respir J"},{"key":"4481_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N Macintyre","year":"2005","unstructured":"Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pederson OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720\u2013735. https:\/\/doi.org\/10.1183\/09031936.05.00034905","journal-title":"Eur Respir J"},{"key":"4481_CR17","first-page":"1892","volume":"20","author":"PJ Clements","year":"1993","unstructured":"Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Silman AJ, Allegar N, Varga J, Massa M (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892\u20131896","journal-title":"J Rheumatol"},{"key":"4481_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1378\/chest.85.6.751","volume":"85","author":"DA Mahler","year":"1984","unstructured":"Mahler DA, Weinberg DH, Wells CK, Feinstein AR (1984) The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85:751\u2013758. https:\/\/doi.org\/10.1378\/chest.85.6.751","journal-title":"Chest"},{"key":"4481_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13075-016-1015-0","volume":"18","author":"PD Shenoy","year":"2016","unstructured":"Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S (2016) Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 18:123. https:\/\/doi.org\/10.1186\/s13075-016-1015-0","journal-title":"Arthritis Res Ther"},{"key":"4481_CR20","doi-asserted-by":"publisher","first-page":"e0177107","DOI":"10.1371\/journal.pone.0177107","volume":"12","author":"M Baqir","year":"2017","unstructured":"Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH (2017) Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience. PLoS ONE 12:e0177107. https:\/\/doi.org\/10.1371\/journal.pone.0177107","journal-title":"PLoS ONE"},{"key":"4481_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","volume":"45","author":"SNC Liossis","year":"2006","unstructured":"Liossis SNC, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45:1005\u20131008. https:\/\/doi.org\/10.1093\/rheumatology\/kei211","journal-title":"Rheumatology (Oxford)"},{"key":"4481_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","volume":"102","author":"AC Zamora","year":"2008","unstructured":"Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, Golden JA (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Resp Med 102:150\u2013155. https:\/\/doi.org\/10.1016\/j.rmed.2007.07.021","journal-title":"Resp Med"},{"key":"4481_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1378\/chest.06-2861","volume":"133","author":"AJ Gerbino","year":"2008","unstructured":"Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma- associated interstitial lung disease. Chest 133:455\u2013460. https:\/\/doi.org\/10.1378\/chest.06-2861","journal-title":"Chest"},{"key":"4481_CR24","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00296-019-04357-x","volume":"39","author":"K Melissaropoulos","year":"2019","unstructured":"Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D (2019) Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 39:1961\u20131970. https:\/\/doi.org\/10.1007\/s00296-019-04357-x","journal-title":"Rheumatol Int"},{"key":"4481_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L et al (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76:1207\u20131218. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210503","journal-title":"Ann Rheum Dis"},{"key":"4481_CR26","doi-asserted-by":"publisher","first-page":"e000384","DOI":"10.1136\/rmdopen-2016-000384","volume":"3","author":"M Boonstra","year":"2017","unstructured":"Boonstra M, Meijs J, Dorjee AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK (2017) Rituximab in early systemic sclerosis. RMD Open 3:e000384. https:\/\/doi.org\/10.1136\/rmdopen-2016-000384","journal-title":"RMD Open"},{"key":"4481_CR27","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s10067-015-2902-5","volume":"34","author":"LI Sakkas","year":"2015","unstructured":"Sakkas LI, Simopoulou T, Katsiari C, Bogdanos D, Chikanza IC (2015) Early systemic sclerosis- opportunities for treatment. Clin Rheumatol 34:1327\u20131331. https:\/\/doi.org\/10.1007\/s10067-015-2902-5","journal-title":"Clin Rheumatol"},{"key":"4481_CR28","volume-title":"User\u2019s manual for the SF-36v2 Health Survey","author":"ME Maruish","year":"2011","unstructured":"Maruish ME (2011) User\u2019s manual for the SF-36v2 Health Survey, 3rd edn. Quality Metric Incorporated, Lincoln, RI","edition":"3"},{"key":"4481_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10067-014-2525-2","volume":"33","author":"PT Chan","year":"2014","unstructured":"Chan PT, Mok CC, Chan KL, Ho LY (2014) Functioning and health-related quality of life in Chinese patients with systemic sclerosis: a case control study. Clin Rheumatol 33:659\u2013666. https:\/\/doi.org\/10.1007\/s10067-014-2525-2","journal-title":"Clin Rheumatol"},{"key":"4481_CR30","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/rheumoatology\/kep295","volume":"48","author":"CT Derk","year":"2009","unstructured":"Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48:1595\u20131599. https:\/\/doi.org\/10.1093\/rheumoatology\/kep295","journal-title":"Rheumatology (Oxford)"},{"key":"4481_CR31","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/rheumatology\/kep284","volume":"48","author":"D Khanna","year":"2009","unstructured":"Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP (2009) Minimally important differences in the Mahler\u2019s transition dyspnoea index in a large randomized controlled trial- results from the scleroderma lung study. Rheumatology (Oxford) 48:1537\u20131540. https:\/\/doi.org\/10.1093\/rheumatology\/kep284","journal-title":"Rheumatology (Oxford)"},{"key":"4481_CR32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/ard.2010.142000","volume":"70","author":"EN Le","year":"2011","unstructured":"Le EN, Wigley FM, Shah AA, Boin F, Hummers LK (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104\u20131107. https:\/\/doi.org\/10.1136\/ard.2010.142000","journal-title":"Ann Rheum Dis"},{"key":"4481_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","volume":"21","author":"D Khanna","year":"2019","unstructured":"Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP (2019) Minimal clinically important differences for the modified Rodnan skin score: results from the scleroderma lung studies (SLS-I and SLS-II). Arthritis Res Ther 21:23. https:\/\/doi.org\/10.1186\/s13075-019-1809-y","journal-title":"Arthritis Res Ther"},{"key":"4481_CR34","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"FA Mendoza","year":"2012","unstructured":"Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39:1241\u20131247. https:\/\/doi.org\/10.3899\/jrheum.111229","journal-title":"J Rheumatol"},{"key":"4481_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/0970-2113.148369","volume":"32","author":"S Dhooria","year":"2015","unstructured":"Dhooria S, Agarwal R, Gupta D (2015) Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases? Lung India 32:4\u20135. https:\/\/doi.org\/10.4103\/0970-2113.148369","journal-title":"Lung India"},{"key":"4481_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/0970-2113.148451","volume":"32","author":"ZF Udwadia","year":"2015","unstructured":"Udwadia ZF, Mullerpattan JB, Balakrishnan C, Richeldi L (2015) Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India 32:50\u201352. https:\/\/doi.org\/10.4103\/0970-2113.148451","journal-title":"Lung India"},{"key":"4481_CR37","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, Khalidi A, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina A (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. J Rheumatol 43:1672\u20131679. https:\/\/doi.org\/10.3899\/jrheum.151322","journal-title":"J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04481-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04481-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04481-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:41:48Z","timestamp":1607215308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04481-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,7]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4481"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04481-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,7]]},"assertion":[{"value":"24 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GSRSNK Naidu, Shefali Khanna Sharma, Adarsh MB, Varun Dhir, Anindita Sinha, Sahajal Dhooria and Sanjay Jain declare that they have no conflict of interest. All the authors declare that they have no relationship with the organization promoting MMF.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"A written informed consent was obtained from all the participants included in this study and no identifying information of any participant was included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the Institute of Ethics Committee (Ref. No. NK\/2612\/DM\/10772). All the procedures performed in this study were in accordance to the guidelines set up by the Declaration of Helsinki in 1964 and later amended in 2000.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}